Silvia Novello

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 566 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

K.M. Kerr, L. Bubendorf, Martin J. Edelman et al. · Annals of Oncology · 2014 · 300 citations · Full text

Medicine, Oncology, Pathology +17

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters, Rafał Dziadziuszko, Alessandro Morabito et al. · Nature Medicine · 2022 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant Osimertinib for Resectable <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Jianxing He, Masahiro Tsuboi, Walter Weder et al. · Journal of Clinical Oncology · 2025 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +17